Fifth Third Bancorp reduced its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 2.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,276 shares of the medical research company’s stock after selling 2,211 shares during the period. Fifth Third Bancorp’s holdings in IQVIA were worth $19,700,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Compass Financial Management LLC increased its position in shares of IQVIA by 31.9% during the third quarter. Compass Financial Management LLC now owns 157 shares of the medical research company’s stock worth $42,000 after purchasing an additional 38 shares in the last quarter. North Dakota State Investment Board boosted its position in shares of IQVIA by 0.8% in the 3rd quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock valued at $1,361,000 after purchasing an additional 40 shares during the period. Boston Trust Walden Corp boosted its position in shares of IQVIA by 1.9% in the 3rd quarter. Boston Trust Walden Corp now owns 2,650 shares of the medical research company’s stock valued at $712,000 after purchasing an additional 50 shares during the period. Apella Capital LLC boosted its position in shares of IQVIA by 4.7% in the 3rd quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after purchasing an additional 55 shares during the period. Finally, Brighton Jones LLC grew its stake in IQVIA by 0.7% during the 3rd quarter. Brighton Jones LLC now owns 8,151 shares of the medical research company’s stock worth $2,191,000 after buying an additional 58 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.
IQVIA Stock Performance
Shares of IQV stock opened at $265.44 on Friday. The stock has a fifty day moving average price of $267.55 and a 200 day moving average price of $211.88. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. The stock has a market cap of $43.74 billion, a PE ratio of 32.25, a P/E/G ratio of 2.41 and a beta of 1.16. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50.
IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.26 by $0.08. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same quarter in the prior year, the company earned $3.00 earnings per share. IQVIA’s revenue was up 8.0% compared to the same quarter last year. Sell-side analysts forecast that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.
Insider Activity
In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the transaction, the insider owned 24,989 shares of the company’s stock, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.70% of the stock is owned by insiders.
Analysts Set New Price Targets
A number of brokerages have weighed in on IQV. Deutsche Bank reduced their price objective on IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Stifel Nicolaus raised their target price on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Royal Bank Of Canada lifted their target price on shares of IQVIA from $247.00 to $319.00 and gave the company an “outperform” rating in a report on Tuesday, September 29th. UBS Group began coverage on shares of IQVIA in a research report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target for the company. Finally, Weiss Ratings cut shares of IQVIA from a “hold (c+)” rating to a “sell (d+)” rating in a research note on Wednesday, October 28th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $294.21.
Check Out Our Latest Research Report on IQVIA
IQVIA Company Profile
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Read More
- Five stocks we like better than IQVIA
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
